In Silico HTS and Structure Based Optimization of Indazole-Derived ULK1 Inhibitors
摘要:
We present the outcome of an in silico high throughput screen (HTS) and optimization of a small molecule Unc-51-Like Kinase 1 (ULK1) inhibitor hit, SR-17398, with an indazole core. Docking studies guided design efforts that led to inhibitors with increased activity vs ULK1 (IC50 < 50 nM). The most advanced molecules in this inhibitor series (3a and 3g) hold promise for further development into selective ULK1 molecular probes to interrogate the biology of ULK1 and to assess whether selectively targeting autophagy is an effective anticancer strategy.
[EN] BENZAMIDE DERIVATIVES AS CGAS-STING PATHWAY AGONISTS<br/>[FR] DÉRIVÉS DE BENZAMIDE UTILISÉS EN TANT QU'AGONISTES DE LA VOIE CGAZ-STING
申请人:BARUCH S BLUMBERG INST
公开号:WO2020072492A1
公开(公告)日:2020-04-09
Pharmaceutical compositions of the invention comprise functionalized benzamide derivatives useful as cyclic GMP-AMP synthase- Stimulator of interferon gene (cGAS-STING) pathway agonists, and useful for treating viral diseases and boost antitumor immunity.
BENZAMIDE DERIVATIVES AS CGAS-STING PATHWAY AGONISTS
申请人:Baruch S. Blumberg Institute
公开号:US20210347752A1
公开(公告)日:2021-11-11
Pharmaceutical compositions of the invention comprise functionalized benzamide derivatives useful as cyclic GMP-AMP synthase-Stimulator of interferon gene (cGAS-STING) pathway agonists, and useful for treating viral diseases and boost antitumor immunity.
<i>In Silico</i> HTS and Structure Based Optimization of Indazole-Derived ULK1 Inhibitors
作者:Spencer D. Wood、Wayne Grant、Isabel Adrados、Jun Yong Choi、James M. Alburger、Derek R. Duckett、William R. Roush
DOI:10.1021/acsmedchemlett.7b00344
日期:2017.12.14
We present the outcome of an in silico high throughput screen (HTS) and optimization of a small molecule Unc-51-Like Kinase 1 (ULK1) inhibitor hit, SR-17398, with an indazole core. Docking studies guided design efforts that led to inhibitors with increased activity vs ULK1 (IC50 < 50 nM). The most advanced molecules in this inhibitor series (3a and 3g) hold promise for further development into selective ULK1 molecular probes to interrogate the biology of ULK1 and to assess whether selectively targeting autophagy is an effective anticancer strategy.